Patent application number | Description | Published |
20090053233 | Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations - The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of FcγRIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma. | 02-26-2009 |
20090130094 | Cytotoxic Antibodies Directed Against Antibodies Inhibiting Factor VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 05-21-2009 |
20090305228 | Potentiation of Apoptosis by Monoclonal Antibodies - The present invention relates to the use of an antibodies composition, the fucose content of which is less than 65%, for indicating apoptosis in vitro. | 12-10-2009 |
20100098706 | MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR - The invention relates to a monoclonal antibody directed against the human LDL (Low Density Lipoprotein) receptor, in which the variable region of each of the light chains is coded by the murine nucleic acid sequence SEQ ID NO: 5, the variable region of each of the heavy chains is coded by the murine nucleic acid sequence SEQ ID NO: 7, or by nucleic acid sequences having a sufficient homology with the sequences SEQ ID NO: 5 and SEQ ID NO: 7 so that the nature and the affinity of the bond between the antibody and its antigene are not modified, while the constant regions of the light chains and the heavy chains thereof are constant regions from a non-murine species. | 04-22-2010 |
20100143370 | SET OF MEANS FOR TREATING A MALIGNANT PATHOLOGY, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE - Kit of parts for treating a malignant pathology, an auto-immune disease or an infectious disease, comprising an effector cell which expresses the FcγRIII receptor (CD16) on its surface, and a monoclonal antibody, the affinity of the Fc region of said monoclonal antibody for CD16 being greater than the affinity of the Fc region of the polyclonal immunoglobulins for CD16. | 06-10-2010 |
20100303826 | Use of ADCC-Optimized antibodies for treating weak patients - The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism. | 12-02-2010 |
20110052571 | METHOD FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA USING MONOCLONAL ANTIBODIES - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP). | 03-03-2011 |
20110059072 | METHOD FOR TREATING CANCER USING MONOCLONAL ANTIBODIES - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP). | 03-10-2011 |
20110059073 | METHOD FOR TREATING INFECTIOUS DISEASE USING MONOCLONAL ANTIBODIES - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP). | 03-10-2011 |
20110274684 | CYTOTOXIC ANTIBODIES DIRECTED AGAINST ANTIBODIES INHIBITING FACTOR VIII - The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A. | 11-10-2011 |
20110311556 | ANTI-RHESUS D MONOCLONAL ANTIBODY - The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4. | 12-22-2011 |
20120258096 | ANTI-D MONOCLONAL ANTIBODIES - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP). | 10-11-2012 |
20140017243 | USE OF ADCC-OPTIMIZED ANTIBODIES FOR TREATING WEAK PATIENTS - The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism. | 01-16-2014 |